Australasian experience and trials in sentinel lymph node biopsy: The RACS SNAC trial

Asian Journal of Surgery

Volumn 27, Issue 4, 2004, Pages 284-290

  Ung, Owen A ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TECHNETIUM SULFIDE TC 99M; DISULFINE BLUE;

ADULT; AGE; AGED; AUSTRALIA; AXILLARY LYMPH NODE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NEW ZEALAND; OUTCOMES RESEARCH; PALPATION; PERFORMANCE; PERITUMORAL DRUG ADMINISTRATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SYMPTOM;

EID: 7044240795     PISSN: 10159584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1015-9584(09)60052-X     Document Type: Conference Paper

References (17)

1. Fredriksson I, Liljegren G, Arnesson LG, et al. Consequences of axillary recurrence after conservative breast surgery. Br J Surg 2002;89:902-8.
2. Weir L, Speers C, D'yachkova Y, et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20:1793-9.
3. Polednak AP. Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg 2003;237:163-7.
4. Kissin MW, Querci-Della-Rovere G, Easton D, et al. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986;73:580-4.
5. Aitken RJ, Gayes MN, Rodger A, et al. Arm morbidity within a trial of mastectomy and either node sample with selective radiotherapy or axillary clearance. Br J Surg 1989;76:568-71.
6. Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002;9:248-55.
7. Tanis PJ, Niewig OE. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer 2002:87;705-10.
8. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy in breast cancer. Ann Surg 1994;220:391-401.
9. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997;349:1864-7.
10. Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-53.
11. Kollias J, Gill PG, Chatterton BE, et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med J Aust 1999;171:461-5.
12. National Health and Medical Research Council. Clinical Practice Guidelines - Management of Early Breast Cancer. Eastwood, NSW: Stone Press, 1995.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
14. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-68.
15. Baxter NN. The body image after breast cancer questionnaire: the design and testing of a disease specific measure. Diss Abstr Int 1999;59(12-B):6258.
16. Casley-Smith JR. Measuring and representing peripheral oedema and its alterations. Lymphology 1994;27:56-70.
17. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53.